Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for curing osteoarthritis

A kind of osteoarthritis and composition technology, applied in the field of compositions for treating osteoarthritis

Inactive Publication Date: 2008-05-21
BEIJING SUNHO PHARMA
View PDF2 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But there have been no studies combining the three together to treat osteoarthritis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for curing osteoarthritis
  • Pharmaceutical composition for curing osteoarthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1 The influence of the present invention on the apoptosis of chondrocytes caused by nitroprusside

[0028] Reagents and drugs: type II collagenase, trypsin, dimethyl sulfoxide, blue tetrazolium (MTT), toluidine stain, DMEM medium, fetal bovine serum, nitroprusside (SNP)

[0029] Animals: 2-3 days old clean grade New Zealand rabbits for cell culture

[0030] Preparation, culture and identification of rabbit chondrocytes in vitro: take newborn New Zealand rabbits, kill them and disinfect them with alcohol, cut off the limbs of young rabbits under aseptic conditions on an ultra-clean workbench, and separate the muscles and joint capsules around the shoulders, elbows and knee joints. Cut unossified cartilage tissue, put it into a petri dish, add a little 10% FBS DMEM culture solution, cut it into 1mm×1mm with ophthalmic scissors, and centrifuge (1500r / min) for 5min at room temperature. After removing the supernatant, move the cartilage tissue into a flask, add d...

Embodiment 2

[0037] Embodiment 2 Composition of the present invention induces arthritis experiment on rat kaolin

[0038] Animals: 70 female rats with a body weight of 130-150 g were randomly divided into 7 groups, which were respectively the control group and the second to seventh raw drug compounding experimental groups. The control group was administered with normal saline, and the experimental group was given a dose of 0.2g / kg BW

[0039] Experimental method: intragastric administration of the test substance, 1 hour later, conventional disinfection of the ankle toe joint of the right hind limb and injection of 0.2ml of 10% sterilized kaolin normal saline suspension, 1, 3, 5 days after injection, by volumetric measurement method The volume (ml) of the left and right hind paws was measured. Give the test substance every day, and after 5 days, inject 1% Evans blue into the tail vein according to the amount of 1ml / kg BW, and 2 hours after the injection, kill the animal after ether anesthe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for the treatment of osteoarthritis, the composition of the invention consists of 5 to 10 weight parts of glucosamine hydrochloride, 5 to 10 weight parts of sodium chondroitin sulfate and 1 to 4 weight parts of sodium hyaluronate, and the needed oral formulation can be prepared by adopting the conventional preparation technology along with acceptable excipients in pharmacy. The pharmaceutical composition of the invention has the functions of prevention and treatment of osteoarthritis, so the invention can be used in the preparation of the drugs for the prevention and treatment of osteoarthritis and can also be used as the health care food which has the function of prevention of osteoarthritis.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating osteoarthritis, in particular to a composition for treating osteoarthritis composed of glucosamine hydrochloride, chondroitin sulfate and sodium hyaluronate. Background technique [0002] Osteoarthritis (OA) is a chronic degenerative bone joint disease that endangers the health of middle-aged and elderly people. Clinically, knee osteoarthritis is the most common. With the increase of the world's aging population, the incidence of OA is increasing year by year, which seriously affects the quality of life of middle-aged and elderly people. Its clinical manifestations are joint pain, swelling and dysfunction. The main pathological changes are articular cartilage degeneration, subchondral Bone lesions, along with changes in the synovium, ultimately lead to degradation of the cartilage matrix, chondrocyte death, and loss of structural integrity of the joint. The etiology of OA is multiface...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/737A61P19/02A61K31/728A61K31/7008
Inventor 张树祥熊国裕
Owner BEIJING SUNHO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products